TaiRx, Inc.

TaiRx, Inc. develops and commercializes therapeutics for cancer and other diseases. Its pipeline includes CVM-1118, an oral anti-cancer drug in Phase II clinical trials, and the pre-clinical candidates TRX-920, an oral delivery formulation, and TRX-105, a molecule for treating and alleviating symptoms of various forms of colitis. The company also offers Zelnite for the treatment of selenium deficiency and is developing nodal diagnostic devices and antibody drugs for use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.